ArticleFrontiers in neurology
Serial assessment of the novel biomarker MFGE8 in comparison with GFAP for predicting severity and outcome after traumatic brain injury.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early assessment of traumatic brain injury (TBI) severity and prognosis is critical for clinical diagnosis and treatment. However, existing biomarkers have limitations in terms of predictive accuracy and timeliness. This study aimed to investigate the dynamic changes of the novel biomarker milk fat globule-EGF factor 8 (MFGE8) following TBI and systematically evaluate its value in predicting TBI severity and clinical prognosis, in comparison to GFAP. Methods: This was a prospective, single-center observational study involving 70 patients with acute TBI and 33 healthy controls. Serum levels of MFGE8 and GFAP were quantitatively determined by ELISA at admission (within 12 h of injury) and at 24, 48, and 72 h after injury. TBI severity was graded by the Glasgow Coma Scale (GCS) at admission, and the Rotterdam CT score was used to evaluate radiological injury severity. Outcome measures included 30-day mortality and the Glasgow Outcome Scale-Extended (GOSE) score at 3 months. Longitudinal biomarker trajectories and their associations with clinical severity, radiological severity, and outcomes were analyzed using linear mixed-effects models (LMMs), with Spearman's correlation and receiver operating characteristic (ROC) analyses performed as complementary assessments. Results: The levels of serum MFGE8 and GFAP in TBI patients at all time points were significantly higher than those in the control group ( Conclusion: Serum MFGE8 is a promising biomarker after TBI. It is closely related to the injury severity and clinical prognosis. Particularly, it demonstrates high prognostic predictive value within 24 h post-injury. Continuous monitoring of MFGE8 may aid in early risk stratification and prognostic assessment for TBI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.